Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of first US patent for Chronocort®

6 Sep 2017 07:00

RNS Number : 9085P
Diurnal Group PLC
06 September 2017
 

6 September 2017

 

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Diurnal announces grant of first US patent for Chronocort®

 

Composition of matter patent provides protection until 2033 in key US market where Chronocort® has already received Orphan Drug Designation

 

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the grant by the US Patent and Trademark Office (USPTO) of its first US patent for Chronocort®, the Company's second late-stage product.

 

US 9,750,704, entitled "Delayed and Immediate Release Formulation", is a pharmaceutical composition of matter patent protecting the Chronocort® proprietary formulation as a treatment for congenital adrenal hyperplasia (CAH) and adrenal insufficiency (AI).  The patent provides in-market protection until 2033.

 

This patent expands the Company's exclusivity position in the US, where Chronocort® has already received Orphan Drug Designation for the treatment of both CAH and AI from the US Food and Drug Administration (FDA), which provides the potential for seven years of market exclusivity awarded on approval.

 

The US is expected to be a major territory for sales of Chronocort®, with CAH and AI collectively estimated to affect 140,000 patients and have an addressable market of approximately $1bn. In addition to the on-going European Phase III trial, Diurnal has submitted a proposed Phase III pivotal US registration study design and supporting data package for Chronocort® for the treatment of CAH to the FDA and, subject to their agreement, expects to commence this study around the end of 2017.

 

Martin Whitaker, CEO of Diurnal, commented: 

"This new patent for Chronocort® provides in-market protection until 2033 in the US, a key target market for Diurnal, in addition to the potential for market exclusivity provided by the award of Orphan Drug Designation for both CAH and AI. With patents now extending protection in the US for both Chronocort® and Infacort® to 2033 and 2034, respectively, we are confident that, if approved, these products will enjoy a long period of exclusivity in the US market."

 

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Numis Securities Ltd (Nominated Adviser)

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Paul Gillam, Freddie Barnfield

Corporate Broking: James Black

Panmure Gordon (UK) Limited (Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley / Duncan Monteith

Corporate Broking: Tom Salvesen

FTI Consulting

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

Notes to Editors

 

About Congenital Adrenal Hyperplasia

Congenital Adrenal Hyperplasia (CAH) is an orphan condition usually caused by deficiency of the enzyme 21-hydroxylase. This enzyme is required to produce the adrenal steroid hormone, cortisol. The block in the cortisol production pathway causes the over-production of male steroid hormones (androgens), which are precursors to cortisol. The condition is congenital (inherited at birth) and affects both sexes. The cortisol deficiency and over-production of male sex hormones can lead to increased mortality, infertility and severe development defects including ambiguous genitalia, premature (precocious) sexual development and short stature. Sufferers, even if treated, remain at risk of death through an adrenal crisis.

 

Approximately two thirds of CAH patients are estimated to have poor disease control, leading to elevated androgen levels. The condition is estimated to affect approximately 71,000 patients in Europe (51,000) and the US (20,000), with approximately 405,000 in the rest of the world.

 

Current therapy for CAH uses a combination of generic steroids (hydrocortisone, dexamethasone and prednisolone) and, at best, these adequately treat approximately one third of CAH patients. Other therapies being developed are at an early stage of development and not expected to receive approval in the short-term.

 

About Adrenal Insufficiency

Adrenal Insufficiency (AI) is a condition characterised by deficiency in cortisol, an essential hormone in regulating metabolism and the response to stress. AI is either primary or secondary with primary AI resulting from diseases intrinsic to the adrenal gland (e.g. Addison's diseases where auto-immune destruction of the adrenal glands occurs) and secondary AI resulting from pituitary diseases (e.g. hypopituitarism) where there is a failure in signalling and stimulation of cortisol secretion. AI has been identified as an orphan disease in Europe and the US where there are estimated to be approximately 400,000 patients. Currently there are no optimal hydrocortisone preparations in the US specifically designed to treat these patients where patients are often administered a variety of non-physiological steroid therapies. These often result in poor control of disease can result in chronic fatigue leading to a poor quality of life in adulthood resulting in increased morbidity and mortality.

 

About Chronocort®

Chronocort® is a modified release hydrocortisone preparation that has been designed to mimic the natural circadian rhythm of cortisol when given in a twice-a-day "toothbrush" regimen (last thing at night before sleep and first thing in the morning on waking). Chronocort has been granted Orphan Drug Designations in Europe and the US in the treatment of Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI). The first planned indication for Chronocort® is CAH. Chronocort® has completed three Phase I trials in 2011, 2012 and 2015 (food effects study), a Phase II trial in CAH patients in 2014 in the US and is currently in Phase III trials in Europe.

 

In Europe, Chronocort® already benefits from Orphan Drug Designations for both CAH and AI, providing the potential to be granted market exclusivity for 10 years post market authorisation. The pivotal Phase III trial for Chronocort® in Europe continues to progress well, with over 75% of patients recruited at the end of the financial year, and is scheduled to complete in the first half of 2018, implying a potential market authorisation in Europe could be forthcoming around the end of 2019.

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDKMGGLLKNGNZM
Date   Source Headline
30th Apr 20193:40 pmRNSHolding(s) in Company
30th Apr 20192:43 pmRNSHolding(s) in Company
26th Apr 20195:52 pmRNSDirector Dealings and Issue of Equity
26th Apr 20193:10 pmRNSHolding(s) in Company
25th Apr 20197:15 amEQSHardman & Co Research: Diurnal Group (DNL): Clarity for Chronocort regulatory pathway
24th Apr 20197:00 amRNSGrant of Orphan Drug Designation in Australia
11th Apr 20197:00 amRNSPositive Scientific Advice from EMA for Chronocort
28th Mar 20197:00 amRNSDiurnal signs marketing and distribution agreement
28th Mar 20197:00 amRNSInterim Results
20th Mar 20197:00 amRNSUpdate on Alkindi US development
25th Feb 20197:00 amRNSSubmission of MAA for Alkindi and Second Patent
11th Feb 201911:00 amRNSNotice of Interim Results
17th Jan 20197:00 amRNSDirector Dealings
16th Jan 20197:15 amEQSHardman & Co Research: Diurnal Group (DNL): Chronocort - seeking regulatory advice
10th Jan 201912:18 pmRNSStatement regarding Price Movement
10th Jan 20197:00 amRNSGrant of second US patent for Chronocort
24th Dec 20187:00 amRNSDirector Dealings and Issue of Equity
12th Dec 20184:02 pmRNSDirector Dealings
11th Dec 20187:00 amRNSRegulatory package for Scientific Advice in Europe
4th Dec 20181:08 pmRNSDirector/PDMR Shareholding
14th Nov 201811:38 amRNSResults of Annual General Meeting
14th Nov 201810:16 amRNSIssue of Equity and Exercise of Options
18th Oct 20187:15 amEQSHardman & Co Research: Diurnal Group (DNL): Unexpected Phase III trial outcome
17th Oct 20187:00 amRNSUpdate on late-stage development pipeline
8th Oct 20184:00 pmRNSPosting of Annual Report and AGM Notice
8th Oct 20182:45 pmRNSSMC Approves The Use of Alkindi
8th Oct 20187:00 amRNSHeadline Data for Chronocort European Phase III
5th Oct 20187:00 amRNSFirst patients enrolled in US Chronocort Phase III
20th Sep 20187:00 amRNSResults for the year ended 30 June 2018
15th Aug 201811:11 amRNSUpdate on Alkindi® in Germany
10th Jul 20181:36 pmRNSDirector/PDMR Shareholding
21st Jun 20187:00 amRNSNotice of Results
18th Jun 20184:54 pmRNSDirector/PDMR Shareholding
18th May 20183:33 pmRNSDirector Dealings
18th May 20181:11 pmRNSAppointment of NOMAD and Joint Broker
15th May 20188:13 amRNSLaunch of Alkindi for paediatric AI in Germany
11th May 20182:41 pmRNSDirector Declaration
17th Apr 20183:58 pmRNSHolding(s) in Company
5th Apr 20182:08 pmRNSDirector/PDMR Shareholding
5th Apr 20188:01 amRNSDirector/PDMR Shareholding
3rd Apr 20182:39 pmRNSResult of GM and Completion of £10.5m Placing
21st Mar 20187:15 amRNSHardman & Co: New capital funds commercial plans
20th Mar 20185:20 pmRNSPlacing Update
14th Mar 20188:47 amRNSProposed Placing
12th Mar 20187:00 amRNSAppointment of CRO to support US Chronocort trials
12th Mar 20187:00 amRNSHalf-year Report
22nd Feb 20187:00 amRNSDiurnal announces grant of first patents in Japan
19th Feb 20187:00 amRNSCommercialisation agreement in Australia and NZ
13th Feb 20187:00 amRNSEuropean marketing authorisation for Alkindi®
12th Feb 20187:00 amRNSCompletion of patient enrolment in EU Phase III

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.